Stay updated with breaking news from Mindset Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.
Collectively referred to as the "Transaction"). The Transaction constituted a reverse takeover of the Company by FTP under applicable securities laws. FTP became a...
A first-of-its-kind trial testing a novel psilocin-based drug for major depressive disorder (MDD) has been approved by the UK MHRA.
Echelon Capital Markets analyst Stefan Quenneville in a recent report reiterated a “Speculative Buy” rating on Mindset Pharma stock.
Commercial trial to treat major depressive disorder with psychedelic drugs given green light by MHRA